Celgene presents results of Iberdomide-Dexamethasone combination study
Category: #health  By Pankaj Singh  Date: 2019-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Celgene presents results of Iberdomide-Dexamethasone combination study

Celgene Corporation, a U.S.-based biotechnology company recently announced first clinical results evaluating CC-220 (Iberdomide) in combination with dexamethasone in patients with relapsed & refractory multiple myeloma from a Phase 1/2 study, cites source.

Reportedly, the results included preliminary safety & efficacy data from the study which aims to determine maximum tolerated dose and the recommended phase 2 dose of Iberdomide in combination with dexamethasone. Iberdomide is Celgene’s patented cereblon E3 ligase modulator compound with enhanced tumoricidal & immune stimulatory effects proven in preclinical studies. In the phase 1/2 study, approximately 300 participants are expected to enroll.

As per reliable sources, 66 patients at a median age of 65 received the Iberdomide and dexamethasone combination, in 8 incremental doses ranging from 0.3 mg-1.3 mg. Increasing Iberdomide doses were given on days 1 to 21 in along with dexamethasone on days 1, 8, 15 & 22 of each 28-day cycle. The patients had a median of 5 prior multiple myeloma treatments. The treatments could have included- proteasome inhibitors & daratumumab, stem cell transplant and immunomodulatory drugs including lenalidomide & pomalidomide.

Adverse events reported included peripheral sensory neuropathy (1.5%), pulmonary embolism (1.5%), thrombocytopenia (12%), anemia (24%), infection (26%) and neutropenia (29%). Treatment was discontinued by 6 patients due to adverse events. Out of 66 patients who received the combination, 59 were evaluable for response. The overall response rate was 32%, out of which 29% achieved a partial response and 2 patients achieved very good partial response.

Dr. Alise Reicin, President of Global Clinical Development, Celgene was reportedly quoted saying that the preliminary clinical activity & favorable safety data observed with the combination of Iberdomide & dexamethasone are encouraging, particularly in patients who experienced failed therapies, including patients who were refractory to pomalidomide or daratumumab & lenalidomide.

Patients who were refractory to immunomodulatory medications, that included lenalidomide & pomalidomide, had an overall response rate of 35% with 33% patients achieving partial response & 1 patient recorded very good partial response.

Source credits: https://ir.celgene.com/press-releases/press-release-details/2019/Celgene-Presents-Data-from-a-Phase-12-Clinical-Study-of-Iberdomide-in-Combination-with-Dexamethasone-in-Patients-with-Relapsed-and-Refractory-Multiple-Myeloma-at-ASCO-2019/default.aspx



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Experian takes over MyHealthDirect for patient engagement and access
Experian takes over MyHealthDirect for patient engagement and access
By Pankaj Singh

  • MyHealthDirect’s easy-to-understand technology guides its patients to profound and right care.
  • Acquisition of MyHealthDirect would strengthen...

Amazon rolls out Scout autonomous delivery robots in California
Amazon rolls out Scout autonomous delivery robots in California
By Pankaj Singh

  • The company brings out its 6-wheeled, sidewalk-driving delivering robot for delivery in the Irvine area of California.
     
  • The driverless...

hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
By Pankaj Singh

This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects.

hVIVO plc has re...